pharmaphorum August 15, 2022
Phil Taylor

In draft guidance, NICE has said that AliveCor’s ECG recording device should be an option to check or heart disturbances in patients who take antipsychotic medicines.

The KardiaMobile 6L – first introduced in 2019 – is an update to AliveCor’s earlier ECG with an additional electrode to make it a six-lead device that improves the accuracy of heart rhythm measurements.

Like its predecessor, it links to a smartphone app which includes an artificial intelligence system that can detect for example whether atrial fibrillation, bradycardia (slow heart rhythm), tachycardia (fast heart rhythm) or a normal rhythm is detected.

The draft guidance (PDF) cover use of the device and app for people taking antipsychotics, who need to be tested before and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Medical Devices, Patient / Consumer, Provider, Technology
Neuronetics wins FDA clearance for device to treat adolescents with depression
J&J in talks to buy Shockwave Medical: WSJ
Roche develops continuous glucose monitor with predictive algorithms
MedCity Pivot: A Conversation About Wearable Robots with Scott Davis
Masimo to hive off consumer business, including FDA-cleared baby monitor, health smartwatch

Share This Article